BioAge Labs (NASDAQ:BIOA) Insider Paul Rubin Sells 7,433 Shares
by Michael Walen · The Markets DailyBioAge Labs, Inc. (NASDAQ:BIOA – Get Free Report) insider Paul Rubin sold 7,433 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $18.75, for a total transaction of $139,368.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
BioAge Labs Trading Down 0.9%
BIOA stock traded down $0.19 during trading on Tuesday, hitting $19.91. 381,085 shares of the company’s stock were exchanged, compared to its average volume of 1,006,004. BioAge Labs, Inc. has a 52-week low of $2.88 and a 52-week high of $24.00. The business has a 50-day moving average price of $14.71 and a two-hundred day moving average price of $8.85. The stock has a market capitalization of $713.77 million, a price-to-earnings ratio of -13.10 and a beta of 1.40.
BioAge Labs (NASDAQ:BIOA – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million during the quarter.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in BIOA. Millennium Management LLC increased its stake in BioAge Labs by 749.8% during the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock worth $1,803,000 after buying an additional 270,479 shares during the period. Marshall Wace LLP grew its stake in shares of BioAge Labs by 324.7% during the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after acquiring an additional 173,388 shares in the last quarter. Geode Capital Management LLC increased its position in shares of BioAge Labs by 60.8% during the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after acquiring an additional 171,426 shares during the last quarter. Stonepine Capital Management LLC lifted its stake in shares of BioAge Labs by 202.2% in the second quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock worth $624,000 after acquiring an additional 101,085 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after purchasing an additional 93,694 shares during the last quarter.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on BIOA. Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a report on Tuesday. Citigroup upped their target price on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Piper Sandler assumed coverage on BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.00.
Get Our Latest Stock Report on BIOA
BioAge Labs Company Profile
BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.
At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.